Child & Adolescent Immunization Schedule Recommendations for Ages 18 Years or Younger, United States, 2024 미국 18세 미만 소아 청소년 권장 예방 접종. Source -Red Book

Child & Adolescent Immunization Schedule

Recommendations for Ages 18 Years or Younger, United States, 2024. Red Book 에서 퍼온 글

24년 미국 18세 미만 소아 청소년 권장 예방 접종

Using the schedule

To make vaccination recommendations, healthcare providers should:

Determine recommended vaccine by age (Table 1)
Determine recommended interval for catch-up vaccination (Table 2)
Assess need for additional recommended vaccines by medical condition or other indication (Table 3)
Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
Review contraindications and precautions for vaccine types (Appendix)
Review new or updated ACIP guidance (Addendum)

For Parents

Parent-friendly schedules

Vaccines your child may need: Get a personalized list of recommended vaccines

Get email updates

The Immunization Schedule

Vaccines in the schedule

Table 1. By age

Table 2. Catch-up schedule

Table 3. By medical indications

Vaccination notes

Appendix

Addendum

Download the Schedule

More Schedule Resources

Legend

Range of recommended ages for all children

Range of recommended ages
for catch-up vaccination

Range of recommended ages for certain high-risk groups

Recommended vaccination can begin in this age group

Recommended vaccination based on shared clinical decision-making

No recommendation/
not applicable

Birth to 15 Months

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).

child vaccine schedule Birth to 15 Months
Vaccine and other immunizing agents	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos
Respiratory syncytial virus (RSV-mAb [Nirsevimab])	1 dose depending on maternal RSV vaccination status, See notes					1 dose (8 through 19 months), See notes
Hepatitis B (HepB)	1^st dose	←2^nd dose→			←3^rd dose→
Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series)			1^st dose	2^nd dose	See notes
Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs)			1^st dose	2^nd dose	3^rd dose			←4^th dose→
Haemophilus influenzae type b (Hib)			1^st dose	2^nd dose	See notes		←3^rd or 4^th dose, See notes→
Pneumococcal conjugate (PCV15, PCV20)			1^st dose	2^nd dose	3^rd dose		←4^th dose→
Inactivated poliovirus (IPV: <18 yrs)			1^st dose	2^nd dose	←3^rd dose→
COVID-19 (1vCOV-mRNA, 1vCOV-aPS)					1 or more doses of updated (2023–2024 Formula) vaccine (See notes)
Influenza (IIV4)					Annual vaccination 1 or 2 doses
Influenza (LAIV4)
Measles, mumps, rubella (MMR)					See notes		←1^st dose→
Varicella (VAR)							←1^st dose→
Hepatitis A (HepA)					(See notes)		←2-dose series, See notes→
Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)
Human papillomavirus (HPV)
Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)			See notes
Meningococcal B (MenB-4C, MenB-FHbp)
Respiratory syncytial virus vaccine (RSV [Abrysvo])
Dengue (DEN4CYD: 9-16 yrs)
Mpox

18 Months to 18 Years

child vaccine schedule 18 Months to 18 Years
Vaccine and other immunizing agents	18 mos	2-3 yrs	4-6 yrs	11-12 yrs	16 yrs
Respiratory syncytial virus (RSV-mAb [Nirsevimab])	1 dose (8 through 19 months), See notes
Hepatitis B (HepB)	←3^rd dose→
Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series)
Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs)	←4^th dose→		5^th dose
Haemophilus influenzae type b (Hib)
Pneumococcal conjugate (PCV15, PCV20)
Inactivated poliovirus (IPV: <18 yrs)	←3^rd dose→		4^th dose			See notes
COVID-19 (1vCOV-mRNA, 1vCOV-aPS)	1 or more doses of updated (2023–2024 Formula) vaccine (See notes)
Influenza (IIV4)	Annual vaccination 1 or 2 doses			Annual vaccination 1 dose only
Influenza (LAIV4)		Annual vaccination 1 or 2 doses		Annual vaccination 1 dose only
Measles, mumps, rubella (MMR)			2^nd dose
Varicella (VAR)			2^nd dose
Hepatitis A (HepA)	← 2-dose series, See notes→
Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)				1 dose
Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)				1 dose
Human papillomavirus (HPV)				See notes
Human papillomavirus (HPV)				See notes
Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)	See notes			1^st dose	2^nd dose
Meningococcal B (MenB-4C, MenB-FHbp)				See notes
Meningococcal B (MenB-4C, MenB-FHbp)
Respiratory syncytial virus vaccine (RSV [Abrysvo])				Seasonal administration during pregnancy, See notes
Dengue (DEN4CYD: 9-16 yrs)				Seropositive in endemic dengue areas (See notes)
Mpox

Determine recommended interval for catch-up vaccination (Table 2)

Assess need for additional recommended vaccines by medical condition or other indication (Table 3)

Top of Page

Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

Notes

For vaccination recommendations for persons ages 19 years or older, see the Recommended Adult Immunization Schedule, 2024.

Additional information

For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.
Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-2, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization.
Information on travel vaccination requirements and recommendations is available at https://www.cdc.gov/travel/.
For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice Guidelines for Immunization, Immunization in Special Clinical Circumstances (In: Kimberlin DW, Barnett ED, Lynfield Ruth, Sawyer MH, eds. Red Book: 2021–2024 Report of the Committee on Infectious Diseases. 32nd ed. Itasca, IL: American Academy of Pediatrics; 2021:72–86).
For information about vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.
The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All vaccines included in the child and adolescent vaccine schedule are covered by VICP except for dengue, PPSV23, RSV, Mpox, and COVID-19 vaccines. Mpox and COVID-19 vaccines are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.

COVID-19 vaccination
(minimum age: 6 months [Moderna and Pfizer-BioNTech COVID-19 vaccines], 12 years [Novavax COVID-19 Vaccine])

Dengue Vaccination
(minimum age: 9 years)

Diphtheria, tetanus, and pertussis (DTaP) vaccination
(minimum age: 6 weeks [4 years for Kinrix® or Quadracel®])

Haemophilus influenzae type b vaccination
(minimum age: 6 weeks)

Hepatitis A vaccination
(minimum age: 12 months for routine vaccination)

Hepatitis B vaccination
(minimum age: birth)

Human papillomavirus vaccination
(minimum age: 9 years)

Influenza vaccination
(minimum age: 6 months [IIV], 2 years [LAIV4], 18 years [recombinant influenza vaccine, RIV4])

Measles, mumps, and rubella vaccination
(minimum age: 12 months for routine vaccination)

Meningococcal serogroup A,C,W,Y vaccination
(minimum age: 2 months [MenACWY-CRM, Menveo], 2 years [MenACWY-TT, MenQuadfi]), 10 years [MenACWY-TT/MenB-FHbp, Penbraya])

Meningococcal serogroup B vaccination
(minimum age: 10 years [MenB-4C, Bexsero^®; MenB-FHbp, Trumenba^®; MenACWY-TT/MenB-FHbp, Penbraya^™])

Mpox vaccination
(minimum age: 18 years [Jynneos®])

Pneumococcal vaccination
(minimum age: 6 weeks [PCV15], [PCV 20]; 2 years [PPSV23])

Poliovirus vaccination
(minimum age: 6 weeks)

Respiratory syncytial virus immunization
(minimum age: birth [Nirsevimab, RSV-mAb (Beyfortus™)

Respiratory syncytial virus vaccination
(RSV [Abrysvo™])

Rotavirus vaccination
(minimum age: 6 weeks)

Tetanus, diphtheria, and pertussis (Tdap) vaccination
(minimum age: 11 years for routine vaccination, 7 years for catch-up vaccination)

Varicella vaccination
(minimum age: 12 months)

Appendix – Guide to Contraindications and Precautions to Commonly Used Vaccines

Adapted from Table 4-1 in Advisory Committee on Immunization Practices (ACIP) General Best Practice Guidelines for Immunization: Contraindication and Precautions, Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season, Contraindications and Precautions for COVID-19 Vaccination, and Contraindications and Precautions for JYNNEOS Vaccination.

COVID-19 and Flu Vaccines

child schedule appendix for COVID-19 and Influenza vaccines
Vaccines and other Immunizing Agents	Contraindicated or Not Recommended¹	Precautions²
COVID-19 mRNA vaccines [Pfizer-BioNTech, Moderna]	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of an mRNA COVID-19 vaccine⁵	Diagnosed non-severe allergy (e.g., urticaria beyond the injection site) to a component of an mRNA COVID-19 vaccine⁵; or non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of an mRNA COVID-19 vaccine Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine Multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A) Moderate or severe acute illness, with or without fever
COVID-19 protein subunit vaccine [Novavax]	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of a Novavax COVID-19 vaccine⁵	Diagnosed non-severe allergy (e.g., urticaria beyond the injection site) to a component of Novavax COVID-19 vaccine⁵; or non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of a Novavax COVID-19 vaccine Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine Multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A) Moderate or severe acute illness, with or without fever
Influenza, egg-based, inactivated injectable (IIV4)	Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency) Severe allergic reaction (e.g., anaphylaxis) to any vaccine component³ (excluding egg)	Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Moderate or severe acute illness with or without fever
Influenza, cell culture-based inactivated injectable (ccIIV4)[Flucelvax Quadrivalent]	Severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency, or to any component³ of ccIIV4	Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, RIV, or LAIV of any valency. If using ccIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever
Influenza, recombinant injectable (RIV4) [Flublok Quadrivalent]	Severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, or to any component³ of RIV4	Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, ccIIV, or LAIV of any valency. If using RIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever
Influenza, live attenuated (LAIV4) [Flumist Quadrivalent]	Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency) Severe allergic reaction (e.g., anaphylaxis) to any vaccine component³ (excluding egg) Children age 2–4 years with a history of asthma or wheezing Anatomic or functional asplenia Immunocompromised due to any cause including, but not limited to, medications and HIV infection Close contacts or caregivers of severely immunosuppressed persons who require a protected environment Pregnancy Cochlear implant Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear or any other cranial CSF leak Children and adolescents receiving aspirin or salicylate-containing medications Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days.	Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Asthma in persons age 5 years old or older Persons with underlying medical conditions (other than those listed under contraindications) that might predispose to complications after wild-type influenza virus infection [e.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus) Moderate or severe acute illness with or without fever

When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization.
When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization.
Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. See Package inserts for U.S.-licensed vaccines.
See package inserts and FDA EUA fact sheets for a full list of vaccine ingredients. mRNA COVID-19 vaccines contain polyethylene glycol (PEG).

Other Vaccines

child schedule appendix for other vaccines
Vaccines and other Immunizing Agents	Contraindicated or Not Recommended¹	Precautions²
Dengue (DEN4CYD)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised) Lack of laboratory confirmation of a previous Dengue infection	Pregnancy HIV infection without evidence of severe immunosuppression Moderate or severe acute illness with or without fever
Diphtheria, tetanus, pertussis (DTaP)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ For DTaP only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP or DTaP	Guillain-Barré syndrome (GBS) within 6 weeks after previous dose of tetanus-toxoid–containing vaccine History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid–containing or tetanus-toxoid–containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid-containing vaccine For DTaP only: Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy; defer DTaP until neurologic status clarified and stabilized Moderate or severe acute illness with or without fever
Haemophilus influenzae type b (Hib)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Less than age 6 weeks	Moderate or severe acute illness with or without fever
Hepatitis A (HepA)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ including neomycin	Moderate or severe acute illness with or without fever
Hepatitis B (HepB)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3 including yeast Pregnancy: Heplisav-B and PreHevbrio are not recommended due to lack of safety data in pregnant persons. Use other hepatitis B vaccines if HepB is indicated⁴.	Moderate or severe acute illness with or without fever
Hepatitis A-Hepatitis B vaccine (HepA-HepB) [Twinrix]	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ including neomycin and yeast	Moderate or severe acute illness with or without fever
Human papillomavirus (HPV)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Pregnancy: HPV vaccination not recommended	Moderate or severe acute illness with or without fever
Measles, mumps, rubella (MMR) Measles, mumps, rubella, and varicella (MMRV)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised) Pregnancy Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent	Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product) History of thrombocytopenia or thrombocytopenic purpura Need for tuberculin skin testing or interferon-gamma release assay (IGRA) testing Moderate or severe acute illness with or without fever For MMRV only: Personal or family (i.e., sibling or parent) history of seizures of any etiology
Meningococcal ACWY (MenACWY) (MenACWY-CRM) [Menveo] (MenACWY-TT) [MenQuadfi]	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ For MenACWY-CRM only: severe allergic reaction to any diphtheria toxoid–or CRM197–containing vaccine For MenACWY-TT only: severe allergic reaction to a tetanus toxoid-containing vaccine	For MenACWY-CRM only: Preterm birth if less than age 9 months Moderate or severe acute illness with or without fever
Meningococcal B (MenB) MenB-4C [Bexsero] MenB-FHbp [Trumenba]	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³	Pregnancy For MenB-4C only: Latex sensitivity Moderate or severe acute illness with or without fever
Meningococcal ABCWY (MenACWY-TT/MenB-FHbp) [Penbraya]	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe allergic reaction to a tetanus toxoid-containing vaccine	Moderate or severe acute illness, with or without fever
Mpox [Jynneos]	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³	Moderate or severe acute illness, with or without fever
Pneumococcal conjugate (PCV)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe allergic reaction (e.g., anaphylaxis) to any diphtheria-toxoid– containing vaccine or its component³	Moderate or severe acute illness with or without fever
Pneumococcal polysaccharide (PPSV23)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³	Moderate or severe acute illness with or without fever
Poliovirus vaccine, inactivated (IPV)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³	Pregnancy Moderate or severe acute illness with or without fever
RSV monoclonal antibody (RSV-mAb)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component⁵	Moderate or severe acute illness with or without fever
Respiratory syncytial virus vaccine (RSV)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³	Moderate or severe acute illness with or without fever
Rotavirus (RV) RV1 [Rotarix], RV5 [RotaTeq]	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe combined immunodeficiency (SCID) History of intussusception	Altered immunocompetence other than SCID Chronic gastrointestinal disease RV1 only: Spina bifida or bladder exstrophy Moderate or severe acute illness with or without fever
Tetanus, diphtheria, and acellular pertussis (Tdap) Tetanus, diphtheria (Td)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ For Tdap only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP, DTaP, or Tdap	Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of tetanus-toxoid–containing vaccine History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid–containing or tetanus-toxoid–containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid–containing vaccine For Tdap only: Progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized Moderate or severe acute illness with or without fever
Varicella (VAR)	Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised) Pregnancy Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent	Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product) Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination) Use of aspirin or aspirin-containing products Moderate or severe acute illness with or without fever If using MMRV, see MMR/MMRV for additional precautions

When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization.
When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization.
Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. See package inserts for U.S.-licensed vaccines.
For information on the pregnancy exposure registries for persons who were inadvertently vaccinated with Heplisav-B or PreHevbrio while pregnant, please visit heplisavbpregnancyregistry.com/ or www.prehevbrio.com/#safety.
Full prescribing information for BEYFORTUS (nirsevimab-alip) www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf

Addendum – Child and Adolescent Recommended Immunization Schedule for Ages 18 Years or Younger, United States, 2024

In addition to the recommendations presented in the previous sections of this immunization schedule, ACIP has approved the following recommendations by majority vote since October 26, 2023. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in Morbidity and Mortality Weekly Report (MMWR).

Vaccines

Recommendations

Effective Date of
Recommendation*

No new vaccines or vaccine recommendations to report

Vaccines and Other Immunizing Agents in the Child and Adolescent Immunization Schedule*

New Vaccines and Other Immunizing Agents added to the Schedule (See Addendum)

Monoclonal antibody
Monoclonal antibody	Abbreviation(s)	Trade name(s)
Respiratory syncytial virus monoclonal antibody (Nirsevimab)	RSV-mAb	Beyfortus^™

child acronyms
Vaccines	Abbreviation(s)	Trade name(s)
COVID-19^†	1vCOV-mRNA	Comirnaty^®/Pfizer- BioNTech COVID-19 Vaccine
	1vCOV-mRNA	Spikevax^®/Moderna COVID-19 Vaccine
	1vCOV-aPS	Novavax COVID-19 Vaccine
Dengue vaccine	DEN4CYD	Dengvaxia^®
Diphtheria, tetanus, and acellular pertussis vaccine	DTaP	Daptacel^® Infanrix^®
Haemophilus influenzae type B vaccine	Hib (PRP-T)	ActHIB^® Hiberix^®
Haemophilus influenzae type B vaccine	Hib (PRP-OMP)	PedvaxHIB^®
Hepatitis A vaccine	HepA	Havrix^® Vaqta^®
Hepatitis B vaccine	HepB	Engerix-B^® Recombivax HB^®
Human papillomavirus vaccine	HPV	Gardasil 9^®
Influenza vaccine (inactivated)	IIV4	Multiple
Influenza vaccine (live, attenuated)	LAIV4	FluMist^® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II^®Priorix^®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-CRM	Menveo^®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-TT	MenQuadfi^®
Meningococcal serogroup B vaccine	MenB-4C	Bexsero^®
Meningococcal serogroup B vaccine	MenB-FHbp	Trumenba^®
Meningococcal serogroup A, B, C, W, Y vaccine	MenACWY-TT/MenB-FHbp	Penbraya^™
Mpox vaccine	Mpox	Jynneos^®
Pneumococcal conjugate vaccine	PCV15	Vaxneuvance^™
Pneumococcal conjugate vaccine	PCV20	Prevnar 20^®
Pneumococcal polysaccharide vaccine	PPSV23	Pneumovax 23^®
Poliovirus vaccine (inactivated)	IPV	Ipol^®
Respiratory syncytial virus vaccine	RSV	Abrysvo^™
Rotavirus vaccine	RV1 RV5	Rotarix^® RotaTeq^®
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel^® Boostrix^®
Tetanus and diphtheria vaccine	Td	Tenivac^® TDvax™
Varicella vaccine	VAR	Varivax^®

Combination vaccines (use combination vaccines instead of separate injections when appropriate)

(Use combination vaccines instead of separate injections when appropriate)

Vaccines	Abbreviation(s)	Trade name(s)
DTaP, hepatitis B, and inactivated poliovirus vaccine	DTaP-HepB-IPV	Pediarix^®
DTaP, inactivated poliovirus, and Haemophilus influenzae type B vaccine	DTaP-IPV/Hib	Pentacel^®
DTaP and inactivated poliovirus vaccine	DTaP-IPV	Kinrix^® Quadracel^®
DTaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine	DTaP-IPV-Hib-HepB	Vaxelis^®
Measles, mumps, rubella, and varicella vaccines	MMRV	ProQuad^®

*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for
extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit.
The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

Top of Page

Recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease Control and Prevention (CDC), American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), American College of Obstetricians and Gynecologists (ACOG), American College of Nurse-Midwives (ACNM), American Academy of Physician Associates (AAPA), and National Association of Pediatric Nurse Practitioners (NAPNAP).

The comprehensive summary of the ACIP recommended changes made to the child and adolescent immunization schedule can be found in the January 11, 2024 MMWR.

Report

Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800-822-7967)

Questions or comments
Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.

Helpful information